These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27049350)

  • 1. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
    Yeom DH; Lee YS; Ryu I; Lee S; Sung B; Lee HB; Kim D; Ahn JH; Ha E; Choi YS; Lee SH; You WK
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
    Zhou R; Wang S; Wen H; Wang M; Wu M
    Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
    Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
    BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
    Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
    Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
    Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
    Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C
    MAbs; 2016; 8(3):562-73. PubMed ID: 26864324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta-like 4/Notch signaling and its therapeutic implications.
    Yan M; Plowman GD
    Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a recombinant anti-VEGFR2-EPCAM bispecific antibody to improve antiangiogenic efficiency.
    Barzaman K; Samadi M; Moradi-Kalbolandi S; Majidzadeh-A K; Salehi M; Jalili N; Jazayeri MH; Khorammi S; Darvishi B; Siavashi V; Shekarabi M; Farahmand L
    Exp Cell Res; 2021 Aug; 405(2):112685. PubMed ID: 34090863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin.
    Kou G; Shi J; Chen L; Zhang D; Hou S; Zhao L; Fang C; Zheng L; Zhang X; Liang P; Zhang X; Li B; Guo Y
    Cancer Lett; 2010 Dec; 299(2):130-6. PubMed ID: 20826049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression and association of VEGF and Dll4/Notch pathway molecules under hypoxia in patients with lung cancer.
    Yu S; Sun J; Zhang J; Xu X; Li H; Shan B; Tian T; Wang H; Ma D; Ji C
    Histol Histopathol; 2013 Feb; 28(2):277-84. PubMed ID: 23275310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
    Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
    Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
    Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
    Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y; Peng A; He S; Shao X; Nie C; Chen L
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
    Mueller T; Freystein J; Lucas H; Schmoll HJ
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.